Brain scans to track thinking changes after SRS radiation for brain metastases
Official title: MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study looks at whether brain scans can show thinking changes after radiation.
Read our full plain-language summary
What the trial team says
Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. The overarching goal of this study is to better understand the determinants of RT-associated changes in white and gray matter function and associated neurocognitive decline.
Key facts
- Registry number
- NCT04073966
- Conditions studied
- Brain Metastases, Neurocognitive Deficit, White Matter Alterations, Radiation Exposure
Where it is running
This trial lists 1 site.
-
North Carolina
- University of North Carolina at Chapel Hill, Department of Radiation Oncology (Chapel Hill)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.